Cape Verde vs Lithuania: Adults (ages 15+) and children (0-14 years) living with HIV
Cape Verde
3,900
in 2024
Lithuania
3,700
in 2024
Cape Verde rank
118th
Lithuania rank
120th
Adults (ages 15+) and children (0-14 years) living with HIV over time
- Cape Verde
- Lithuania
How they compare
Cape Verde currently reports 3,900 against 3,700 in Lithuania, a difference of 200.
That makes Cape Verde's figure about 1.1 times Lithuania's.
Across all 35 years both countries report, Cape Verde has been ahead every year.
Cape Verde ranks 118th and Lithuania ranks 120th of 152 countries.
Cape Verde has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Cape Verde | Lithuania | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 1,324 | 794 | 530 | Cape Verde |
| 2000s | 2,050 | 1,550 | 500 | Cape Verde |
| 2010s | 2,850 | 2,480 | 370 | Cape Verde |
| 2020s | 3,620 | 3,440 | 180 | Cape Verde |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher adults (ages 15+) and children (0-14 years) living with hiv, Cape Verde or Lithuania?
- Cape Verde, at 3,900 against 3,700 in Lithuania as of 2024.
- What is the difference in adults (ages 15+) and children (0-14 years) living with hiv between Cape Verde and Lithuania?
- 200, with Cape Verde ahead.
- How many years of comparable data are there for Cape Verde and Lithuania?
- 35 years are reported by both, from 1990 to 2024.
- How do Cape Verde and Lithuania rank globally for adults (ages 15+) and children (0-14 years) living with hiv?
- Cape Verde ranks 118th and Lithuania ranks 120th of 152 countries.
- Where does this data come from?
- UNAIDS estimates, published as Adults (ages 15+) and children (0-14 years) living with HIV. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Adults and children living with HIV refers to the number of people ages 0-49 (adult ages 15-49 and children ages 0-14) who are infected with HIV.